MIST
Milestone Pharmaceuticals Inc. NASDAQ Listed May 9, 2019$1.29
-1.15%
vs $1.31
Mkt Cap $111.2M
52w Low $1.00
14.3% of range
52w High $3.06
50d MA $1.64
200d MA $1.86
P/E (TTM)
—
EV/EBITDA
—
P/B
2.6x
Debt/Equity
1.4x
ROE
-151.0%
P/FCF
-2.2x
RSI (14)
42.40
ATR (14)
$0.07
Beta
0.69
50d MA
$1.64
200d MA
$1.86
Avg Volume
1.5M
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1111 Dr. Frederik-Philips Boulevard · Montreal, QC H4M 2X6 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.03 | -0.20 | -566.7% | 1.90 | -15.8% | -9.5% | -5.2% | -7.4% | -3.3% | -2.1% | — |
| Mar 20, 2026 | BMO | -0.18 | -0.16 | +11.1% | 1.36 | +0.0% | -7.4% | -7.9% | +7.8% | -8.0% | -9.6% | — |
| Nov 12, 2025 | BMO | -0.17 | -0.12 | +29.4% | 1.93 | +0.0% | -1.6% | +5.3% | +16.0% | +3.9% | -3.3% | — |
| Aug 12, 2025 | BMO | -0.18 | -0.20 | -11.1% | 1.66 | +3.0% | +4.8% | -3.4% | +1.2% | +0.0% | -1.8% | — |
| May 14, 2025 | BMO | -0.19 | -0.31 | -63.2% | 1.17 | +0.0% | -1.7% | +6.1% | +5.7% | +7.8% | -0.7% | — |
| Mar 13, 2025 | BMO | -0.15 | -0.19 | -26.7% | 2.03 | +5.9% | +6.9% | +11.1% | -1.2% | -16.4% | -2.0% | — |
| Nov 12, 2024 | BMO | -0.16 | -0.14 | +12.5% | 1.87 | -1.6% | -1.6% | -1.6% | -6.1% | +0.0% | +2.4% | — |
| Aug 8, 2024 | BMO | -0.19 | -0.14 | +26.3% | 1.41 | +1.4% | +0.0% | +0.0% | +0.0% | +0.0% | -4.3% | — |
| May 13, 2024 | BMO | -0.26 | -0.21 | +19.2% | 1.70 | +2.4% | +1.2% | +0.6% | +1.2% | -0.6% | +0.6% | — |
| Mar 21, 2024 | BMO | -0.30 | -0.32 | -6.7% | 1.56 | +0.0% | +11.5% | -0.6% | +4.6% | -0.6% | -0.6% | — |
| Nov 13, 2023 | BMO | -0.38 | -0.35 | +7.9% | 2.34 | +1.7% | -4.3% | +1.3% | -1.8% | -1.3% | +3.6% | — |
| Aug 10, 2023 | BMO | -0.39 | -0.37 | +5.1% | 3.30 | -0.9% | -3.9% | -1.3% | +2.2% | -3.8% | +0.6% | — |
| May 11, 2023 | AMC | -0.38 | -0.35 | +7.9% | 4.25 | +0.0% | +3.5% | -4.3% | -6.9% | +2.3% | +2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $2.04 | +1.0% | +1.5% | +4.9% | +1.9% | -6.8% | -3.9% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.35 | $2.34 | -0.4% | -6.4% | -2.3% | -3.3% | +3.4% | -3.7% |
| Dec 15 | TD Cowen | Upgrade | Hold → Buy | — | $2.41 | $2.91 | +20.7% | -2.5% | -6.4% | -2.3% | -3.3% | +3.4% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.41 | $2.91 | +20.7% | -2.5% | -6.4% | -2.3% | -3.3% | +3.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.80 | $0.80 | -0.1% | -5.0% | +5.7% | -6.6% | -7.2% | -2.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $0.76 | -66.0% | -60.9% | -9.1% | -5.0% | +5.7% | -6.6% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.23 | +2.8% | +11.1% | -1.2% | -16.4% | -2.0% | -2.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.72 | -1.1% | -6.3% | +1.2% | -0.6% | +20.7% | -4.0% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.04 | -0.5% | -1.5% | -2.0% | +1.0% | +1.0% | -2.5% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.45 | $1.43 | -1.4% | +2.1% | +0.7% | -2.0% | +0.7% | +1.4% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.46 | +4.3% | +2.9% | +2.1% | +2.0% | -2.0% | -1.4% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.37 | +3.8% | +1.5% | +0.7% | -1.5% | +0.0% | +2.3% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.60 | +2.6% | -1.9% | -2.0% | +0.7% | +0.7% | -2.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.73 | +0.0% | +1.2% | -0.6% | +0.6% | -1.7% | +1.7% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.56 | +0.0% | +11.5% | -0.6% | +4.6% | -0.6% | -0.6% |
| Mar 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.55 | $1.49 | -3.9% | +1.9% | -8.2% | +3.4% | +0.7% | +2.0% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.70 | $1.90 | +11.8% | +24.1% | +4.3% | -3.2% | -21.1% | -4.2% |
| Dec 27 | TD Cowen | Maintains | Outperform → Outperform | — | $1.99 | $2.00 | +0.5% | -5.5% | -5.9% | -5.6% | +7.8% | -2.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $3.17 | +0.0% | -1.3% | +2.2% | -3.8% | +0.6% | -1.9% |
| Jun 20 | Jefferies | Downgrade | Buy → Hold | — | $3.50 | $3.47 | -0.9% | -1.7% | -3.5% | -2.7% | -2.5% | -3.5% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $4.16 | +1.5% | +4.9% | +0.0% | -4.7% | -2.9% | +2.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.44 | +0.9% | -4.3% | -6.9% | +2.3% | +2.5% | +4.6% |
| Apr 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.84 | $3.80 | -1.0% | -4.4% | +0.3% | -2.4% | +6.1% | -2.9% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.90 | $3.95 | +1.3% | -1.8% | +2.9% | +1.0% | +2.3% | -2.7% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.75 | +0.3% | -5.3% | -9.6% | +1.9% | +7.7% | +0.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.62 | $4.95 | +7.1% | +0.0% | -5.2% | +3.4% | +0.2% | +0.7% |
| Apr 22 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.15 | $7.50 | +4.9% | -0.7% | -1.3% | -4.6% | -1.3% | -2.1% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.52 | $7.38 | +13.2% | +6.0% | +0.7% | +4.3% | -0.8% | +4.4% |
| Jul 29 | Oppenheimer | Upgrade | Perform → Outperform | — | $8.01 | $8.06 | +0.6% | +9.2% | -1.0% | +0.5% | +8.4% | -0.7% |
| Jul 24 | Jefferies | Upgrade | Hold → Buy | — | $8.91 | $9.00 | +1.0% | -7.1% | +1.8% | -5.0% | +9.2% | -1.0% |
| Mar 25 | Jefferies | Downgrade | Buy → Hold | — | $1.70 | $2.40 | +41.2% | +14.7% | +5.6% | -3.9% | -5.6% | -1.6% |
| Mar 24 | Oppenheimer | Downgrade | Outperform → Perform | — | $14.00 | $3.35 | -76.1% | -87.9% | +14.7% | +5.6% | -3.9% | -5.6% |
| Mar 24 | Piper Sandler | Downgrade | Overweight → Neutral | — | $14.00 | $3.35 | -76.1% | -87.9% | +14.7% | +5.6% | -3.9% | -5.6% |
| Jun 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $20.70 | $20.68 | -0.1% | -3.3% | +1.9% | +0.7% | -3.4% | +0.7% |
| Jun 3 | Jefferies | Maintains | Buy → Buy | — | $20.70 | $20.68 | -0.1% | -3.3% | +1.9% | +0.7% | -3.4% | +0.7% |
No insider trades available.
8-K · 2.02
!! High
Milestone Pharmaceuticals Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
MIST reported 2025 year-end results with regulatory progress in cardiovascular medicine development, signaling potential near-term catalyst events that could impact valuation and stock momentum.
Mar 20
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 6,331,001 | $8M | Added | Mar 2026 |
| 2 | Propel Bio Management, Llc | 4,118,321 | $5M | — | Mar 2026 |
| 3 | Morgan Stanley | 1,563,750 | $3M | Reduced | Dec 2025 |
| 4 | Two Sigma Investments, Lp | 2,317,176 | $3M | Added | Mar 2026 |
| 5 | Marshall Wace, Llp | 1,944,530 | $2M | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 1,093,230 | $2M | Added | Dec 2025 |
| 7 | Millennium Management | 1,544,325 | $2M | Added | Mar 2026 |
| 8 | Toronto Dominion Bank | 750,000 | $2M | — | Dec 2025 |
| 9 | Boxer Capital Management, Llc | 666,666 | $1M | New | Sep 2025 |
| 10 | Point72 Asset Management | 1,085,683 | $1M | Added | Mar 2026 |
| 11 | Lion Point Capital, Lp | 820,000 | $976K | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 519,046 | $618K | Reduced | Mar 2026 |
| 13 | Ubs Group Ag | 494,908 | $589K | Added | Mar 2026 |
| 14 | Citadel Advisors Llc | 196,696 | $234K | Reduced | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 176,504 | $210K | Reduced | Mar 2026 |
| 16 | Simplex Trading, Llc | 149,291 | $178K | New | Mar 2026 |
| 17 | Quadrature Capital Ltd | 149,105 | $177K | New | Mar 2026 |
| 18 | Renaissance Technologies Llc | 129,705 | $154K | New | Mar 2026 |
| 19 | Adar1 Capital Management, Llc | 100,000 | $119K | New | Mar 2026 |
| 20 | Hrt Financial Lp | 62,256 | $74K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index Fund | 74,022 | $127K | Feb 2026 |
| 2 | Invesco NASDAQ Future Gen 200 ETF | 24,586 | $42K | Feb 2026 |
Valuation
Market Cap
$111.2M
Enterprise Value
$61.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.23x
P/B
2.60x
P/S
60.89x
P/FCF
-2.23x
EV/EBITDA
—
Shares Out
83.9M
Financials (TTM)
Revenue
$1.8M
Net Income
-$68.4M
EBITDA
-$61.4M
Free Cash Flow
-$49.3M
Op Cash Flow
-$49.0M
EPS Basic
$-0.75
EPS Diluted
$-0.68
EPS Forward
$-0.43
Gross Margin
94.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$113.6M
Total Liab.
$71.8M
Total Equity
$41.8M
Cash
$106.0M
LT Debt
$57.2M
Book Value/Sh
$0.50
Debt/Equity
1.40x
Current Ratio
8.01
Quick Ratio
7.96
Returns & Growth
ROE
-151.0%
ROA
-55.5%
ROIC
-62.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-11.9%
Price Returns
2W
-12.9%
1M
-21.1%
3M
-17.0%
6M
-47.2%
12M
-12.3%
Technicals
52W High
$3.06
52W Low
$1.00
50d MA
$1.64
200d MA
$1.86
RSI (14)
42.40
ATR (14)
$0.07
Beta
0.69
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.33
High
$8.00
Low
$6.00
Median
$8.00
Data updated apr 26, 2026 12:22pm
· Source: financialmodelingprep.com